skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Randomized trial comparing three fixed combinations of prostaglandins/prostamide with timolol maleate

Original Research

(1980) Views  (630) Full article downloads

Authors: Jaime Pablo Kelly Rigollet, Joan Anton Ondategui, Angels Pasto, et al

Published Date February 2011 Volume 2011:5 Pages 187 - 191
DOI: http://dx.doi.org/10.2147/OPTH.S16666

Jaime Pablo Kelly Rigollet, Joan Anton Ondategui, Angels Pasto, Laura Lop, Institut Català de la Salut, Centre de Atenció Primària MANSO, Eixample esquerra, Barcelona, Spain,
The results of this were first presented in the World Glaucoma Congress, Boston (8–11 July 2009)

Introduction: To evaluate the long-term efficacy and safety of 3 commercially available fixed combinations of prostaglandin analogs or a prostamide with timolol maleate in patients with primary open angle glaucoma or ocular hypertension.
Methods: In this randomized, prospective, single-blind study, intraocular pressure (IOP) was measured after a 1-month washout period and pachymetry was performed before randomizing patients to latanoprost 50 µg/timolol 5 mg/1 mL (L/T), bimatoprost 300 µg/timolol 5 mg/1 mL (B/T), or travoprost 40 µg/timolol 5 mg/1 mL (T/T). IOP was measured monthly for 6 months and then at 12 months by an investigator blinded to the study drug. Adverse reactions were recorded.
Results: 128 cases were included in the study. The 3 treatment groups had similar baseline characteristics and comparable IOP. All 3 combinations decreased IOP by at least 6 mmHg and IOP remained below 21 mmHg throughout the study. At 12 months L/T achieved greater reduction in IOP than the other 2 fixed combinations, but the difference between L/T and B/T was not statistically significant. At 6 months, more B/T-treated patients reported red eye (P < 0.05 vs L/T and T/T). At 12 months, fewer adverse reactions were reported, with no cases of red eye reported for L/T (P = 0.03 vs B/T).
Conclusions: All 3 combinations are effective at lowering IOP but at 12 months L/T and B/T were found to be more effective than T/T. Treatments were well tolerated after 12 months but L/T showed less hyperemia than B/T throughout the study (P < 0.05).

Keywords: bimatoprost/timolol, fixed combinations, intraocular pressure, latanoprost/timolol, ocular hypertension, primary open angle glaucoma, travoprost/timolol.






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Daily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and Sweden
Toxicity of antiglaucoma drugs with and without benzalkonium chloride to cultured human corneal endothelial cells
Diurnal IOP-lowering efficacy and safety of travoprost 0.004% compared with tafluprost 0.0015% in patients with primary open-angle glaucoma or ocular hypertension
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
Perception of risk and benefit in patient-centered communication and care
Steroid response pattern and outcome of pediatric idiopathic nephrotic syndrome: a single-center experience in northwest Iran
Long-term efficacy of adalimumab in the treatment of uveitis associated with juvenile idiopathic arthritis
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
Ocular hypotensive effect and safety of travoprost 0.004%/timolol maleate 0.5% fixed combination after change of treatment regimen from ß-blockers and prostaglandin analogs